Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness: Impact of glycemic control with insulin and relation with clinical outcome

Shock

Volumn 43, Issue 2, 2015, Pages 109-116

  Ingels, Catherine ^a   Derese, Inge ^a   Wouters, Pieter J ^a   Van Den Berghe, Greet ^a   Vanhorebeek, Ilse ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Critical illness; HMGB1; inflammation; RAGE; S100A12; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; CYTOKINE RECEPTOR; INSULIN; LIGAND; PHARMACOLOGICAL BIOMARKER; PROTEIN; PROTEIN S 100; PROTEIN S100A; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; AUTACOID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; S100A12 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD LEVEL; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICAL ILLNESS; DEATH; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN TREATMENT; INTENSIVE CARE; INTENSIVE CARE UNIT; ISCHEMIA; KIDNEY FAILURE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATIVE STRESS; RISK; RISK ASSESSMENT; RISK FACTOR; APACHE; BACTEREMIA; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIGENS, NEOPLASM; APACHE; BACTEREMIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CRITICAL ILLNESS; FEMALE; HMGB1 PROTEIN; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROSPECTIVE STUDIES; S100 PROTEINS;

EID: 84922104240     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000278     Document Type: Article

References (35)

1. Gentile LF, Cuenca AG, Efron PA, Ang D, McKinley BA, Moldawer LL, Moore FA: Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 72:1491-1501, 2012.
2. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, Martin E, Weigand MA: Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 12:201-208, 2008.
3. Bierhaus A, Humpert PM, Morcos M,Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886, 2005.
4. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membranebound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22:3716-3727, 2008.
5. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM: Identification, classification and expression of RAGE gene splice variants. FASEB J 22:1572-1580, 2008.
6. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P: HMGB1: guiding the immunity from within. Trends Immunol 26:381-387, 2005.
7. Wang H, Yang H, Czura Cj, Sama AE: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768-1773, 2001.
8. Ombrellino M, Wang H, Aljemian MS, Talhouk A, Scher LA, Friedman SG, Tracey KJ: Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 354:1446-1447, 1999.
9. Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81:28-37, 2007.
10. Achouiti A, Fö ll D, Vogl T, van Till JW, Laterre PF, Dugernier T, Wittebole X, Boermeester MA, Roth J, van der Poll T, et al.: S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsis. Shock 40:188-194, 2013.
11. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S-I: Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem 44:601-604, 2011.
12. Santili F, Vazzana N, Bucciarelli LG, Davi G: Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Biochem 16:940-952, 2009.
13. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001.
14. Manigrasso MB, Juranek J, Ramasamy R, Scmidt AM: Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab 25:15-22, 2014.
15. Van den Berghe G, Wouters P,Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Eng J Med 345:1359-1367, 2001.
16. Arabi YM, Dehbi M, Rishu AH, Baturcam E, Kahoul SH, Brits RJ, Naidu B, Bouchama A: sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy. Crit Care 15:R203, 2011.
17. Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, Sauaia A, Silliman CC, Banerjee A, Abraham E: HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 32:17-22, 2009.
18. Nawroth PP, Stern DM: Soluble forms of RAGE: an index of vascular stress A commentary on BSoluble RAGE in type 2 diabetes: association with oxidative stress[. Free Radic Biol Med 43:506-510, 2007.
19. Langouche L, Vanhorebeek I, Vlasselaers D, Vander Perre S, Wouters PJ, Skogstrand K, Hansen TK, Van den Berghe G: Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115:2277-2286, 2005.
20. Vanhorebeek I, Ellger B, De Vos R, Boussemaere M, Debaveye Y, Vander Perre S, Rabbani N, Thornalley PJ, Van den Berghe G: Tissue-specific glucose toxicity induces mitochondrial damage in a burn injury model of critical illness. Crit Care Med 37:1355-1364, 2009.
21. Ramasamy R, Schmidt AM: Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep 9:107-116, 2012.
22. Farmer DGS, Kennedy S: RAGE, vascular tone and vascular disease Pharmacol Ther 124:185-194, 2009.
23. Cohen MJ, Carles M, Brohi K, Calfee CS, Rahn P, Call MS, Chesebro BB, West MA, Pittet J-F: Early release of sRAGE after severe trauma in humans. J Trauma 68:1273-1278, 2010.
24. Sadik NAH, Mohamed WA, Ahmed MI: The association of receptor of advanced glycation end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem 359:73-81, 2012.
25. Gohda T, Tanimoto M, Moon J-Y, Gotoh H, Aoki T, Matsumoto M, Shibata T, Oshawa I, Funabiki K, Tomino Y: Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 81:196-201, 2008.
26. Chung KY, Park JJ, Kim YS: The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc 40:2136-2138, 2008.
27. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, et al.: Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 6:718-723, 2011.
28. Butscheid M, Hauptvogel P, Fritz P, Klotz U, Alscher DM: Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease. J Clin Pathol 60:415-418, 2007.
29. D'Adamo E, Giannini C, Chiavaroli V, de Giorgis T, Verrotti A, Chiarelli F, Mohn A: What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children Antioxid Redox Signal 14:1167-1172, 2011.
30. Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, Dolar E: Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 42:802-807, 2009.
31. Germanová A, Muravská A, Jáchymová M, Hájek Z, Kouck] M, Mestek O, Zima T, Kalousová M: Receptor for advanced glycation end products (RAGE) and glyoxalase I gene polymorphisms in pathological pregnancy. Clin Biochem 45:1409-1414, 2012.
32. Brodska H, Malickova K, Valenta J, Fabio A, Drabek T: Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis. Scand J Clin Lab Invest 73:650-660, 2013.
33. Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E: HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 34:1046-1053, 2008.
34. Tseng CC, Fang WF, Leung SY, Chen HC, Chang YC, Wang CC, Chang HC, Lin MC: Impact of serum biomarkers and clinical factors on intensive care unit mortality and 6-month outcome in relatively healthy patients with severe pneumonia and acute respiratory distress syndrome. Dis Markers 2014: 804-654, 2014.
35. Shiotsu Y, Mori Y, Nishimura M, Hatta T, Imada N, Maki N, Iida K, Iwamoto N, Matsuoka E, Tamagaki K, et al.: Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan. BMC Nephrol 14:16, 2013.